The microbiome plays a significant role in shaping the immune system's function and influencing the development of various disorders. Our research aims at studying the impact of microbiome-immune interactions on the development, progression, and treatment of inflammatory bowel disease (IBD) and colorectal cancer (CRC).
Our research revolves around understanding how specific microbes interact with the host, particularly their effects on the immune system, in IBD and CRC. Additionally, we investigate the potential of leveraging the microbiome as a therapeutic option for managing these disorders. We are particularly interested in unraveling the mechanisms employed by bacteria to influence IBD and CRC development, with the ultimate goal of utilizing this knowledge to develop tailored precision medicine approaches.
To achieve our objectives, we employ cutting-edge technologies and utilize state-of-the-art facilities. These include a top-of-the-line germ-free and gnotobiotic animal facility, advanced imaging capabilities, next-generation sequencing devices, untargeted metabolomics lipidomics platforms, and more.
